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Oral drugs stimulating endogenous insulin production (insulin
secretagogues) may have detrimental effects on breast cancer
outcomes. The data presented shows the relationship between
pre-existing insulin secretagogues use, adipokine proﬁles at the
time of breast cancer (BC) diagnosis and subsequent cancer out-
comes in women diagnosed with BC and type 2 diabetes mellitus
(T2DM). The Pearson correlation analysis evaluating the relation-
ship between adipokines stratiﬁed by T2DM pharmacotherapy and
controls is also provided. This information is the extension of the
data presented and discussed in “Insulin use, adipokine proﬁles and
breast cancer prognosis” (Wintrob et al., in press) [1].
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Dubject area Clinical and Translational Research
ore speciﬁc sub-
ject areaBiomarker Research, Cancer Epidemiologyype of data Tables
ow data was
acquiredTumor registry query was followed by vital status ascertainment, and med-
ical records review
Luminexs- or enzyme-linked immunosorbent assay- based quantitation of
adipokines (adiponectin, leptin, C-reactive protein, interleukine-6, inter-
leukine-1β, interleukine-1Ra, tumor necrosis factor-α, and C-peptide) from
plasma samples was conducted.
A Luminexs200TM instrument with Xponent 3.1 software was used to
acquire all data except for C-reactive protein determinations which have
been done using a Synergy 2 BioTek multi-mode readerata format Analyzed
xperimental
factorsAdipokines were determined from the corresponding plasma samples col-
lected at the time of breast cancer diagnosisxperimental
featuresThe dataset included 97 adult females with diabetes mellitus and newly
diagnosed breast cancer (cases) and 194 matched controls (breast cancer
only). Clinical and treatment history were evaluated in relationship with
cancer outcomes and adipokine proﬁles. A biomarker correlation analysis
was also performed.ata source
locationUnited States, Buffalo, NY - 42° 530 50.3592″N; 78° 520 2.658″Wata accessibility The data is with this articleD
Value of the data
 Presented data shows the relationship between pre-existing insulin secretagogues use, adipokine
production at the time of cancer diagnosis and breast cancer outcomes.
 This data serves as a benchmark for future investigations targeting pharmacotherapy-induced
adipokine modulation in breast cancer.
 The data described here can assist study design of further biomarker evaluation in relationship
with the safety and effectiveness of diabetes pharmacotherapy.1. Data
Reported data represents the observed association between insulin secretagogues' utilization and
the adipokine proﬁles at the time of breast cancer diagnosis in women with diabetes mellitus
(Table 1). Data in Table 2 includes the observed correlations between adipokines stratiﬁed by type
2 diabetes mellitus pharmacotherapy and controls.2. Experimental design, materials and methods
Evaluation of adipokine proﬁle association with insulin secretagogue use and BC outcomes was
carried out under two protocols approved by both Roswell Park Cancer Institute (EDR154409 and
NHR009010) and the State University of New York at Buffalo (PHP0840409E). Demographic and
clinical patient information was linked with cancer outcomes and adipokine proﬁles of corresponding
plasma specimen harvested at BC diagnosis and banked in the Roswell Park Cancer Institute Data
Bank and Bio-Repository.
Table 1
Adipokines associations with insulin secretagogue use.
Biomarker Biomarker Grouping Concentration Control No Secretagogue Any Secretagogue Unadjusted p-value (MVP)
p1 p2 p3 Global test
Adiponectin(ng/ml) Median (25–75th) – 14.9 (10.7–22.6) 11.3 (6.89–20.9) 11.7 (8.10–17.6) o0.015 (0.022) 0.008 (0.210) 0.810 (0.770) 0.005 (0.046)
Quartiles 1.79–8.90 38 (19.6%) 17 (36.2%) 18 (36.0%) 0.044 0.047 0.350 0.035
8.97–14.14 48 (24.7%) 12 (25.5%) 13 (26.0%)
14.18–20.52 54 (27.8%) 6 (12.8%) 12 (24.0%)
21.46–68.93 54 (27.8%) 12 (25.5%) 7 (14.0%)
OS-Based Optimization 1.79–7.15 19 (9.8%) 13 (27.7%) 7 (14.0%) 0.002 (0.007) 0.390 (0.780) 0.100 (0.120) 0.005 (0.018)
7.17–68.93n 175 (90.2%) 34 (72.3%) 43 (86.0%)
DFS-Based Optimization 1.79–17.91n 124 (63.9%) 33 (70.2%) 39 (78.0%) 0.420 (0.560) 0.060 (0.210) 0.380 (0.350) 0.150 (0.340)
18.21–68.93 70 (36.1%) 14 (29.8%) 11 (22.0%)
Leptin (ng/ml) Median (25–75th) – 26.0 (16.9–38.0) 23.0 (15.4–44.1) 32.0 (21.8–50.1) 0.820 (0.330) 0.050 (0.120) 0.210 (0.700) 0.150 (0.160)
Quartiles BLQ to 17.00 50 (25.8%) 15 (31.9%) 8 (16.0%) 0.180 0.250 0.180 0.190
17.73–27.07 49 (25.3%) 12 (25.5%) 12 (24.0%)
27.09–41.75 53 (27.3%) 6 (12.8%) 13 (26.0%)
43.06–159.15 42 (21.6%) 14 (29.8%) 17 (34.0%)
OS-Based Optimization BLQ to 6.17n 14 (7.2%) 3 (6.4%) 1 (2.0%) 1.000 (0.640) 0.320 (0.890) 0.350 (0.740) 0.450 (0.850)
6.25–159.15 180 (92.8%) 44 (93.6%) 49 (98.0%)
DFS-Based Optimization BLQ to 50.82 155 (79.9%) 37 (79.9%) 39 (78.0%) 0.860 (0.070) 0.770 (0.002) 0.930 (0.070) 0.950 (0.002)
51.64–159.15n 39 (20.1%) 10 (20.1%) 11 (22.0%)
CRP (μg/ml) Median (25–75th) – 2.10 (0.80–4.65) 2.80 (1.10–5.30) 3.05 (1.30–9.15) 0.340 (0.670) 0.022 (0.370) 0.260 (0.890) 0.060 (0.750)
Quartiles BLQ to 0.90 56 (28.9%) 9 (19.1%) 9 (18.0%) 0.490 0.160 0.770 0.340
1.00–2.20 47 (24.2%) 14 (29.8%) 11 (22.0%)
2.30–5.20 49 (25.3%) 11 (23.4%) 12 (24.0%)
5.30–23.00 42 (21.6%) 13 (27.7%) 18 (36.0%)
OS-Based Optimization BLQ to 8.30 173 (89.2%) 41 (87.2%) 34 (68.0%) 0.001 (0.390) 0.710 (0.580) 0.028 (0.250) 0.001 (0.530)
8.60–23.00n 21 (10.8%) 6 (12.8%) 16 (32.0%)
DFS-Based Optimization BLQ to 16.60 186 (95.9%) 46(97.9%) 45 (90.0%) 1.000 (0.300) 0.150 (0.670) 0.210 (0.180) 0.190 (0.470)
17.20–23.00 8 (4.1%) 1 (2.1%) 5 (10.0%)
IL-6 (pg/ml) Median (25–75th) – 0.7 (0.44–1.76) 1.49 (0.59–3.72) 1.14 (0.51–3.10) 0.010 (0.090) 0.170 (0.740) 0.330 (0.048) 0.024 (0.180)
Quartiles BLQ to 0.44 55 (28.4%) 7 (14.9%) 12 (24.0%) 0.027 0.190 0.670 0.060
0.50–0.70 58 (29.9%) 9 (19.1%) 9 (18.0%)
0.72–2.32 39 (20.1%) 16 (34.0%) 13 (26.0%)
2.51–138.00 42 (21.6%) 15 (31.9%) 16 (32.0%)
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OS-Based Optimization BLQn 18 (9.3%) 0 (0.0%) 1 (2.0%) 0.028 (0.010) 1.000 (0.999) 0.140 (0.300) 0.022 (0.031)
0.34–138.00 176 (90.7%) 47 (100%) 49 (98.0%)
DFS-Based Optimization BLQn 18 (9.3%) 0 (0.0%) 1 (2.0%) 0.028 (0.010) 1.000 (0.999) 0.140 (0.300) 0.022 (0.031)
0.34–138.00 176 (90.7%) 47 (100%) 49 (98.0%)
TNF-α (pg/ml) Median (25–75th) – 5.55 (3.86–8.22) 6.64 (4.41–11.41) 6.53 (4.89–9.20) 0.060 (0.080) 0.080 (0.420) 0.850 (0.300) 0.070 (0.170)
Quartiles BLQ to 4.19 56 (28.9%) 9 (19.1%) 8 (16.0%) 0.060 0.260 0.480 0.120
4.21–5.66 46 (23.7%) 14 (29.8%) 13 (26.0%)
5.67–8.73 51 (26.3%) 7 (14.9%) 14 (28.0%)
8.90–77.00 41 (21.1%) 17 (36.2%) 15 (30.0%)
OS-Based Optimization BLQ to 8.96 153 (78.9%) 31 (66.0%) 36 (72.0%) 0.060 (0.150) 0.300 (0.390) 0.520 (0.650) 0.150 (0.320)
9.00–77.00n 41 (21.1%) 16 (34.0%) 14 (28.0%)
DFS-Based Optimization BLQ to 8.96 153 (78.9%) 31 (66.0%) 36 (72.0%) 0.060 (0.150) 0.300 0.390) 0.520 (0.650) 0.150 (0.320)
9.00–77.00n 41 (21.1%) 16 (34.0%) 14 (28.0%)
IL-1β (pg/ml) Median (25–75th) – 1.60 (1.60–3.20) 1.60 (1.60–3.75) 1.60 (1.60–2.76) 0.170 (0.030) 0.140 (0.250) 0.037 (0.020) 0. 090 (0.011)
OS-Based Optimization BLQ to 13.08n 187 (96.4%) 40 (85.1%) 50 (100%) 0.008 (0.007) 0.350 (0.035) 0.005 (0.001) 0.002 (0.001)
14.74–127.08 7 (3.6%) 7 (14.9%) 0 (0.0%)
DFS-Based Optimization BLQ to 13.08n 187 (96.4%) 40 (85.1%) 50 (100%) 0.008 (0.007) 0.350 (0.035) 0.005 (0.001) 0.002 (0.001)
14.74–127.08 7 (3.6%) 7 (14.9%) 0 (0.0%)
C-peptide (ng/ml) Median (25–75th) – 1.67 (1.17–2.42) 2.36 (1.33–3.20) 2.26 (1.84–3.14 0.050 (0.760) o0.001 (0.041) 0.330 (0.060) o0.001 (0.090)
Quartiles 0.14–1.28 58 (29.9%) 11 (23.4%) 4 (8.0%) 0.043 o0.001 0.140 o0.001
1.29–1.82 59 (30.4%) 7 (14.9%) 7 (14.0%)
1.83–2.68 37 (19.1%) 13 (27.7%) 22 (44.0%)
2.68–9.02 40 (20.6%) 16 (34.0%) 17 (34.0%)
OS-Based Optimization 0.14–0.75n 14 (7.2%) 7 (14.9%) 0 (0%) 0.14 (0.037) 0.080 (0.130) 0.005 (0.001) 0.013 (0.008)
0.76–9.02 180 (92.8%) 40 (85.1%) 50 (100%)
DFS-Based Optimization 0.14–0.75n 14 (7.2%) 7 (14.9%) 0 (0%) 0.140 (0.037) 0.080 (0.130) 0.005 (0.001) 0.013 (0.008)
0.76–9.02 180 (92.8%) 40 (85.1%) 50 (100%)
C-reactive protein (CRP), interleukine-6 (IL-6), interleukine-1β (IL-1β), interleukine-1Ra (IL-1Ra), tumor necrosis factor-α (TNF-α).
n Overall survival (OS)– and disease-free survival (DFS)-optimized biomarker ranges associated with poorer outcomes are represented in bold. BLQ¼below limit of quantitation.
MVP¼p-value of the multivariate adjusted analysis.
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Table 2
Adipokine correlations and secretagogue use.
Compared biomarkers Group Unadjusted correlation Adjusted correlation
Pearson
correlation
95% CI p-value Pearson
correlation
95% CI p-value
C-peptide IL-1β All Subjects (n¼291) 0.089 0.202 to 0.027 0.132 0.081 0.194 to 0.034 0.168
Controls (n¼194) 0.003 0.145 to 0.139 0.967 0.01 0.131 to 0.151 0.891
No Secretagogue (n¼43) 0.265 0.532 to 0.051 0.095 0.285 0.539 to 0.017 0.061
Any Secretagogue (n¼54) 0.069 0.338 to 0.211 0.63 0.105 0.363 to 0.167 0.446
C-peptide IL-1Ra All Subjects (n¼291) 0.081 0.195 to 0.034 0.167 0.073 0.187 to 0.042 0.212
Controls (n¼194) 0.075 0.214 to 0.068 0.304 0.063 0.202 to 0.079 0.382
No Secretagogue (n¼43) 0.171 0.458 to 0.148 0.287 0.18 0.455 to 0.128 0.245
Any Secretagogue (n¼54) 0.064 0.215 to 0.334 0.653 0.004 0.264 to 0.272 0.977
C-peptide IL-6 All Subjects (n¼291) 0.053 0.168 to 0.063 0.368 0.068 0.182 to 0.047 0.244
Controls (n¼194) 0.046 0.187 to 0.097 0.528 0.059 0.198 to 0.083 0.414
No Secretagogue (n¼43) 0.146 0.437 to 0.174 0.366 0.159 0.438 to 0.149 0.306
Any Secretagogue (n¼54) 0.022 0.295 to 0.255 0.879 0.032 0.238 to 0.297 0.819
C-peptide Adiponectin All Subjects (n¼291) 0.163 0.274 to 0.048 0.005 0.178 0.287 to 0.064 0.002
Controls (n¼194) 0.145 0.281 to 0.003 0.045 0.119 0.255 to 0.022 0.098
No Secretagogue (n¼43) 0.343 0.591 to 0.035 0.028 0.388 0.617 to 0.1 0.009
Any Secretagogue (n¼54) 0.086 0.353 to 0.194 0.547 0.068 0.33 to 0.203 0.621
C-peptide Leptin All Subjects (n¼291) 0.161 0.047 to 0.272 0.006 0.238 0.126 to 0.343 o0.001
Controls (n¼194) 0.278 0.141 to 0.404 o0.001 0.314 0.181 to 0.436 o0.001
No Secretagogue (n¼43) 0.042 0.349 to 0.273 0.795 0.001 0.301 to 0.299 0.995
Any Secretagogue (n¼54) 0.03 0.248 to 0.303 0.834 0.144 0.129 to 0.396 0.297
C-peptide CRP All Subjects (n¼291) 0.075 0.188 to 0.041 0.207 0.023 0.092 to 0.137 0.698
Controls (n¼194) 0.117 0.254 to 0.026 0.107 0.042 0.182 to 0.099 0.556
No Secretagogue (n¼43) 0.192 0.127 to 0.475 0.231 0.207 0.099 to 0.478 0.179
Any Secretagogue (n¼54) 0.086 0.353 to 0.194 0.545 –0.014 0.281 to 0.255 0.92
C-peptide TNFα All Subjects (n¼291) 0.012 0.127 to 0.104 0.839 0.035 0.08 to 0.15 0.55
Controls (n¼194) 0.086 0.056 to 0.226 0.234 0.125 0.016 to 0.261 0.082
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No Secretagogue (n¼43) 0.3 0.559 to 0.013 0.057 0.277 0.533 to 0.026 0.069
Any Secretagogue (n¼54) 0.265 0.011 to 0.504 0.057 0.227 0.043 to 0.467 0.096
IL-1β IL-1Ra All Subjects (n¼291) 0.753 0.698 to 0.799 o0.001 0.75 0.695 to 0.797 o0.001
Controls (n¼194) 0.436 0.313 to 0.544 o0.001 0.435 0.313 to 0.542 o0.001
No Secretagogue (n¼43) 0.932 0.874 to 0.964 o0.001 0.929 0.871 to 0.961 o0.001
Any Secretagogue (n¼54) 0.367 0.101 to 0.583 0.007 0.384 0.13 to 0.591 0.004
IL-1β IL-6 All Subjects (n¼291) 0.339 0.232 to 0.437 o0.001 0.337 0.231 to 0.435 o0.001
Controls (n¼194) 0.484 0.367 to 0.586 o0.001 0.476 0.36 to 0.578 o0.001
No Secretagogue (n¼43) 0.69 0.482 to 0.824 o0.001 0.682 0.481 to 0.816 o0.001
Any Secretagogue (n¼54) 0.042 0.237 to 0.314 0.771 0.055 0.216 to 0.318 0.694
IL-1β Adiponectin All Subjects (n¼291) 0.038 0.153 to 0.077 0.515 0.024 0.138 to 0.091 0.685
Controls (n¼194) 0.055 0.195 to 0.088 0.451 0.031 0.171 to 0.11 0.665
No Secretagogue (n¼43) 0.047 0.353 to 0.269 0.773 0.001 0.301 to 0.3 0.996
Any Secretagogue (n¼54) 0.033 0.306 to 0.245 0.818 0.054 0.317 to 0.217 0.695
IL-1β Leptin All Subjects (n¼291) 0 0.116 to 0.115 0.994 0.009 0.124 to 0.106 0.88
Controls (n¼194) 0.072 0.071 to 0.212 0.322 0.081 0.06 to 0.22 0.259
No Secretagogue (n¼43) 0.045 0.351 to 0.27 0.782 0.092 0.382 to 0.214 0.553
Any Secretagogue (n¼54) 0.046 0.317 to 0.233 0.749 0.202 0.446 to 0.069 0.14
IL-1β CRP All Subjects (n¼291) 0.023 0.139 to 0.092 0.693 0.029 0.143 to 0.086 0.623
Controls (n¼194) 0.019 0.16 to 0.124 0.799 0.01 0.151 to 0.131 0.891
No Secretagogue (n¼43) 0.038 0.276 to 0.346 0.813 0.009 0.309 to 0.292 0.953
Any Secretagogue (n¼54) 0.05 0.322 to 0.228 0.724 0.14 0.393 to 0.133 0.31
IL-1β TNFα All Subjects (n¼291) 0.487 0.394 to 0.571 o0.001 0.484 0.391 to 0.568 o0.001
Controls (n¼194) 0.196 0.055 to 0.328 0.007 0.208 0.069 to 0.339 0.004
No Secretagogue (n¼43) 0.668 0.45 to 0.811 o0.001 0.618 0.39 to 0.775 o0.001
Any Secretagogue (n¼54) 0.065 0.334 to 0.215 0.651 0.007 0.274 to 0.261 0.961
IL-1Ra IL-6 All Subjects (n¼291) 0.338 0.231 to 0.436 o0.001 0.335 0.229 to 0.433 o0.001
Controls (n¼194) 0.319 0.186 to 0.441 o0.001 0.31 0.177 to 0.432 o0.001
No Secretagogue (n¼43) 0.759 0.587 to 0.866 o0.001 0.748 0.578 to 0.856 o0.001
Any Secretagogue (n¼54) 0.021 0.256 to 0.295 0.882 0.029 0.294 to 0.241 0.836
IL-1Ra Adiponectin All Subjects (n¼291) 0.043 0.158 to 0.073 0.467 0.049 0.163 to 0.067 0.407
Controls (n¼194) 0.013 0.155 to 0.129 0.859 0.033 0.173 to 0.108 0.643
No Secretagogue (n¼43) 0.077 0.379 to 0.241 0.637 0.064 0.358 to 0.241 0.68
Any Secretagogue (n¼54) 0.105 0.37 to 0.175 0.46 0.147 0.399 to 0.126 0.287
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Table 2 (continued )
Compared biomarkers Group Unadjusted correlation Adjusted correlation
Pearson
correlation
95% CI p-value Pearson
correlation
95% CI p-value
IL-1Ra Leptin All Subjects (n¼291) 0.021 0.095 to 0.136 0.727 0.028 0.087 to 0.143 0.63
Controls (n¼194) 0.017 0.125 to 0.159 0.812 0.055 0.087 to 0.194 0.447
No Secretagogue (n¼43) 0.046 0.269 to 0.353 0.774 0.004 0.296 to 0.304 0.977
Any Secretagogue (n¼54) 0.101 0.366 to 0.18 0.478 -0.131 0.385 to 0.142 0.344
IL-1Ra CRP All Subjects (n¼291) 0.066 0.05 to 0.18 0.263 0.071 0.045 to 0.184 0.229
Controls (n¼194) 0.147 0.005 to 0.283 0.042 0.166 0.026 to 0.3 0.02
No Secretagogue (n¼43) 0.058 0.259 to 0.363 0.722 0.042 0.262 to b0.338 0.79
Any Secretagogue (n¼54) 0.081 0.349 to 0.199 0.569 0.1 0.358 to 0.172 0.47
IL-1Ra TNFα All Subjects (n¼291) 0.529 0.441 to 0.608 o0.001 0.516 0.426 to 0.596 o0.001
Controls (n¼194) 0.456 0.336 to 0.562 o0.001 0.449 0.329 to 0.555 o0.001
No Secretagogue (n¼43) 0.623 0.386 to 0.782 o0.001 0.578 0.335 to 0.748 o0.001
Any Secretagogue (n¼54) 0.202 0.078 to 0.452 0.152 0.203 0.068 to 0.447 0.138
IL-6 Adiponectin All Subjects (n¼291) 0.062 0.176 to 0.054 0.294 0.05 0.164 to 0.066 0.398
Controls (n¼194) 0.103 0.242 to 0.039 0.155 0.088 0.226 to 0.054 0.222
No Secretagogue (n¼43) 0.076 0.242 to 0.378 0.64 0.112 0.195 to 0.399 0.472
Any Secretagogue (n¼54) 0.07 0.339 to 0.209 0.623 0.043 0.307 to 0.228 0.759
IL-6 Leptin All Subjects (n¼291) 0.055 0.061 to 0.169 0.354 0.015 0.101 to 0.129 0.804
Controls (n¼194) 0.054 0.089 to 0.195 0.457 0.01 0.131 to 0.151 0.888
No Secretagogue (n¼43) 0.069 0.248 to 0.372 0.672 0.081 0.225 to 0.372 0.603
Any Secretagogue (n¼54) 0.104 0.176 to 0.369 0.464 0.081 0.191 to 0.341 0.559
IL-6 CRP All Subjects (n¼291) 0.096 0.02 to 0.209 0.104 0.059 0.056 to 0.173 0.315
Controls (n¼194) 0.141 0.001 to 0.277 0.051 0.095 0.047 to 0.233 0.188
No Secretagogue (n¼43) 0.093 0.394 to 0.225 0.564 0.09 0.38 to 0.216 0.562
Any Secretagogue (n¼54) 0.302 0.028 to 0.533 0.029 0.268 0.001 to 0.5 0.047
IL-6 TNFα All Subjects (n¼291) 0.243 0.131 to 0.349 o0.001 0.224 0.112 to 0.33 o0.001
Controls (n¼194) 0.262 0.124 to 0.389 o0.001 0.24 0.102 to 0.368 0.001
No Secretagogue (n¼43) 0.43 0.137 to 0.654 0.005 0.437 0.157 to 0.652 0.003
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Any Secretagogue (n¼54) 0.309 0.036 to 0.539 0.026 0.304 0.039 to 0.528 0.024
Adiponectin Leptin All Subjects (n¼291) 0.085 0.198 to 0.031 0.152 0.15 0.261 to 0.036 0.01
Controls (n¼194) 0.235 0.365 to 0.096 0.001 0.262 0.389 to 0.126 o0.001
No Secretagogue (n¼43) 0.09 0.228 to 0.391 0.577 0.003 0.298 to 0.303 0.986
Any Secretagogue (n¼54) 0.392 0.131 to 0.603 0.004 0.278 0.011 to 0.508 0.04
Adiponectin CRP All Subjects (n¼291) 0.105 0.218 to 0.01 0.073 0.185 0.294 to 0.072 0.002
Controls (n¼194) 0.013 0.154 to 0.13 0.861 0.099 0.237 to 0.043 0.169
No Secretagogue (n¼43) 0.222 0.499 to 0.097 0.165 0.299 0.55 to 0.002 0.049
Any Secretagogue (n¼54) 0.32 0.547 to 0.049 0.02 0.309 0.533 to 0.045 0.021
Adiponectin TNFα All Subjects (n¼291) 0.032 0.147 to 0.084 0.589 0.009 0.124 to 0.106 0.874
Controls (n¼194) 0.031 0.172 to 0.112 0.671 0.011 0.13 to 0.152 0.874
No Secretagogue (n¼43) 0.025 0.334 to 0.289 0.878 0.019 0.283 to 0.318 0.902
Any Secretagogue (n¼54) 0.037 0.309 to 0.241 0.795 0.031 0.296 to 0.239 0.825
Leptin CRP All Subjects (n¼291) 0.103 0.216 to 0.013 0.08 0.114 0.001 to 0.226 0.051
Controls (n¼194) 0.151 0.287 to 0.009 0.036 0.07 0.072 to 0.208 0.334
No Secretagogue (n¼43) 0.141 0.433 to 0.178 0.382 0.165 0.142 to 0.443 0.286
Any Secretagogue (n¼54) 0.052 0.323 to 0.227 0.714 0.173 0.099 to 0.421 0.208
Leptin TNFα All Subjects (n¼291) 0.087 0.029 to 0.2 0.142 0.127 0.012 to 0.238 0.03
Controls (n¼194) 0.03 0.112 to 0.171 0.679 0.094 0.048 to 0.231 0.193
No Secretagogue (n¼43) 0.082 0.236 to 0.384 0.613 0.208 0.099 to 0.478 0.178
Any Secretagogue (n¼54) 0.214 0.065 to 0.463 0.128 0.068 0.203 to 0.33 0.623
TNFα CRP All Subjects (n¼291) 0.021 0.095 to 0.136 0.721 0.056 0.059 to 0.17 0.337
Controls (n¼194) 0.101 0.042 to 0.24 0.164 0.136 0.005 to 0.271 0.058
No Secretagogue (n¼43) 0.032 0.282 to 0.34 0.843 0.072 0.233 to 0.365 0.644
Any Secretagogue (n¼54) 0.076 0.344 to 0.204 0.595 0.126 0.381 to 0.147 0.361
Signiﬁcant correlations are displayed in bolded text. The differences that are only signiﬁcant in either adjusted or unadjusted correlations are further denoted by an outline. C-reactive
protein (CRP), interleukine-6 (IL-6), interleukine-1β (IL-1β), interleukine-1Ra (IL-1Ra), tumor necrosis factor-α (TNF-α), conﬁdence interval (CI).
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As described in the original research article by Wintrob et al. [1], all incident breast cancer cases
diagnosed at Roswell Park Cancer Institute (01/01/2003-12/31/2009) were considered for inclusion
(n¼2194). Medical and pharmacotherapy history were used to determine the baseline presence of
diabetes.
2.2. Inclusion and exclusion criteria
Inclusion criteria were as follows: minimum 18 years of age at diagnosis, presence of pre-existing
diabetes at breast cancer diagnosis, and having available banked treatment-naïve plasma specimens
in the Institute's Data Bank and Bio-Repository. That is, the blood had to be collected prior to the
initiation of any cancer-related therapy (surgery, radiation or pharmacotherapy).
Subjects were excluded if they were male, had prior cancer history or unclear date of diagnosis,
incomplete clinical records, type 1 or unclear diabetes status. For a speciﬁc breakdown of excluded
subjects, please see the original research article by Wintrob et al. [1].
A total of 97 female subjects with breast cancer and baseline diabetes mellitus were eligible for
inclusion in this analysis.
2.3. Control-matching approach
Each of the 97 adult female subjects with breast cancer and diabetes mellitus (deﬁned as “cases”)
was matched with two other female subjects diagnosed with breast cancer, but without baseline
diabetes mellitus (deﬁned as “controls”). The following matching criteria were used: age at diagnosis,
body mass index category, ethnicity, menopausal status and tumor stage (as per the American Joint
Committee on Cancer). Some matching limitations applied [1].
2.4. Demographic and clinical data collection
Clinical and treatment history was documented by medical chart review. Vital status was obtained
from the Institute's Tumor Registry, a local database updated biannually with data obtained from the
National Comprehensive Cancer Networks' Oncology Outcomes Database. Outcomes of interest were
breast cancer recurrence and/or death. For additional details concerning data collection, speciﬁc
deﬁnitions regarding censoring and drug use, and a comprehensive demographic report, please see
the original article [1].
2.5. Plasma specimen storage and retrieval
All the plasma specimens retrieved from long-term storage were individually aliquoted in color
coded vials labeled with unique, subject speciﬁc barcodes. Overall duration of freezing time was
accounted for all matched controls ensuring that the case and matched control specimens had similar
overall storage conditions. Only two instances of freeze-thaw were allowed between biobank retrieval
and biomarker analyses: aliquoting procedure step and actual assay.
2.6. Enzyme-linked immunosorbent assay and Luminexs assays
A total of 7 biomarkers (adiponectin, leptin, C-reactive protein, interleukine-6, interleukine-1β,
interleukine-1Ra, tumor necrosis factor-α, and C-peptide) were quantiﬁed using either enzyme-
linked immunosorbent or Luminexs assays, as described by Wintrob et al. [1]. A quantitative col-
orimetric enzyme-linked immunosorbent assay was performed for detection of C-reactive protein,
according to manufacturer protocol (Genway Biotek Inc., San Diego, CA). The following Luminexs
biomarker panels were utilized in this study: human cytokine/chemokine panel I (MPXHCYTO-60K
for interleukine-1β and interleukine-1Ra), human high sensitivity cytokine/chemokine panel
(HSCYTO-60SK for interleukine-6 and tumor necrosis factorα), human cardiovascular disease panel I
Z.A.P. Wintrob et al. / Data in Brief 10 (2017) 238–247 247(HCVD1-67AK for adiponectin), and human endocrine panel (HENDO-65K for leptin and c-peptide)
produced by Millipore Corporation, Billerica, MA.
2.7. Biomarker-pharmacotherapy association analysis
Biomarker cut-point optimization was performed for each analyzed biomarker. Biomarker levels
constituted the continuous independent variable that was subdivided into two groups that optimized
the log rank test among all possible cut-point selections yielding a minimum of 10 patients in any
resulting group. Quartiles were also constructed. The resultant biomarker categories were then tested
for association with type 2 diabetes mellitus therapy and controls by Fisher's exact test. The con-
tinuous biomarker levels were also tested for association with diabetes therapy and controls across
groups by the Kruskall-Wallis test and pairwise by the Wilcoxon rank sum. Multivariate adjustments
were performed accounting for age, tumor stage, body mass index, estrogen receptor status, and
cumulative comorbidity. The biomarker analysis was performed using R Version 2.15.3. Please see the
original article for an illustration of the analysis workﬂow [1].
Correlations between biomarkers stratiﬁed by type 2 diabetes mellitus pharmacotherapy and
controls were assessed by the Pearson method. Correlation models were constructed both with and
without adjustment for age, body mass index, and the combined comorbidity index. Correlation
analyses were performed using SAS Version 9.4.Funding sources
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